Rezolute, Inc. (RZLT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.96-1.25%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · RZLT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -58.3% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers
RZLT — earnings miss
Dated 2026-09-24
Results of Operations and Financial Condition. On September 24, 2026, Rezolute, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended June 30, 2026. A copy of this press release is attached hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the…
Why it matters: The company reports a cash runway through Q1 2028. Higher costs could shorten that window.
Worry ifThe November 5 report puts cash runway before the end of Q1 2028, or shows higher spending without a longer runway.
Less concerning ifThe November 5 report keeps runway through Q1 2028 or later and shows lower spending.
Why it matters: Rezolute plans to review its filing plan after the tumor HI results. The plan may cover one or both programs.
Watch forAfter the upLIFT results, Rezolute names a BLA path for both programs or gives dates for the next FDA meetings.
Also watch forAfter the upLIFT results, Rezolute delays its BLA plan or names no next FDA step for either program.
Why it matters: This trial tests ersodetug in tumor HI. The result may shape the path toward a filing in 2027.
Watch forAt least 9 of 16 participants meet the 50% glucose-infusion reduction target. The lower 95% confidence bound must be at least 30%.
Also watch forFewer than 9 of 16 participants meet the target, or the lower 95% confidence bound is below 30%.
Why it matters: sunRIZE missed its main goal. A pre-BLA meeting is a path to review, not an approval decision.
Watch forThe FDA holds a pre-BLA meeting and states that the current sunRIZE data can support a BLA filing without a new trial.
Also watch forThe FDA asks for another controlled trial, or says the sunRIZE data cannot support a BLA filing.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$179 on $10,000 · ±1.8% | How much price usually moves either way. |
| Bad day | $813 loss on $10,000 · 8.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,720 loss on $10,000 · 87.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.